A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children
Authors:
Open Access
- 1 June 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 77 (12) , 2318-2323
Abstract
Pharmacokinetically guided dosing was performed in nine paediatric patients receiving etoposide. Doses on day 2 of a 2- or 3-day schedule were adapted on the basis of the day-1 area under the plasma etoposide concentration vs time curve (AUC). The day-1 AUC was estimated using a limited sampling model and the day-2 target AUC defined by the etoposide dose-AUC relationship observed in 33 children. Target AUC values (4.6-8.2 mg ml(-1) x min) were achieved with a high degree of precision and with little bias (mean error 11% and root mean squared error 15% respectively). Pharmacokinetic parameters were similar to those reported previously in children, although interpatient pharmacokinetic variability was less than that observed previously: plasma clearance, 23 (18-26) ml min(-1) m(-2); volume of distribution at steady state (Vdss), 6.0 (3.9-8.9) l m(-2); t(1/2) 254 (127-550) min (median and range). This study has demonstrated that pharmacokinetically guided dosing with etoposide is feasible. However, pharmacokinetically guided dosing is likely to be of most benefit in patients with abnormalities of renal or hepatic function, or in children with prior exposure to cisplatin.Keywords
This publication has 20 references indexed in Scilit:
- Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer.Journal of Clinical Oncology, 1996
- Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation?Journal of Clinical Oncology, 1995
- Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatinClinical Pharmacology & Therapeutics, 1994
- Etoposide admixed with cisplatin. Phase I clinical investigation of 72-hour infusionCancer, 1989
- Drug monitoring of etoposide (VP16-213)Cancer Chemotherapy and Pharmacology, 1987
- PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF 72-HOUR CONTINUOUS INFUSION OF ETOPOSIDE IN PATIENTS WITH ADVANCED CANCER1987
- A phase I trial of continuous infusion VP16-213 (Etoposide)Cancer Chemotherapy and Pharmacology, 1982
- Some suggestions for measuring predictive performanceJournal of Pharmacokinetics and Biopharmaceutics, 1981
- PHASE-I STUDY OF VP-16-213 (ETOPOSIDE) ADMINISTERED AS A CONTINUOUS 5-DAY INFUSION1981
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979